Evidence map›Paper›PMID 38997751›Full record

ArticleRespiratory research2024

The integrin receptor beta

Miri Assayag, Tahrir Obedeyah, Avraham Abutbul, Neville Berkman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miri AssayagDepartment of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel.
Tahrir ObedeyahDepartment of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel.
Avraham AbutbulDepartment of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel.
Neville BerkmanDepartment of Pulmonary Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel. Neville@hadassah.org.il.

Funding

Ministry of Health, State of Israel 3-0000-11030
6 · The paper itself

Abstract

backgroundFibroblast differentiation to a myofibroblast phenotype is a feature of airway remodeling in asthma. Lung fibroblasts express the integrin receptor α

objectivesTo investigate the role of the β7 integrin receptor subunit and α

methodsC57BL/6 wild type (WT) and β7 integrin null mice (β

resultsEosinophil numbers were similar in WT vs β7-/- mice. Prolonged OVA exposure in β7-/- mice was associated with reduced AHR, lung collagen content, peribronchial smooth muscle, lung tissue TGFβ and IL13 expression as compared to WT. Similar findings were observed in WT mice treated with α

conclusionsThe β7 integrin subunit and the α4β7 integrin complex modulate AHR and airway remodeling in a murine model of allergen exposure. This effect is, at least in part, explained by inhibition of fibroblast activation and is independent of eosinophilic inflammation.

Indexed as

Airway RemodelingIntegrin beta ChainsMice, Inbred C57BLMice, KnockoutOvalbuminAllergensAnimalsBronchial HyperreactivityCells, CulturedDisease Models, AnimalFibroblastsLungMiceTransforming Growth Factor betaAllergensintegrin beta7Integrin beta ChainsOvalbuminTransforming Growth Factor betaAirway-hyperresponsivenessAsthmaFibroblastRemodelingα4β7 integrin

Identifiers

PMID38997751
PMCPMC11241790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.